These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 16456808)

  • 1. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
    Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
    Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
    Stevenson JP; Redlinger M; Kluijtmans LA; Sun W; Algazy K; Giantonio B; Haller DG; Hardy C; Whitehead AS; O'Dwyer PJ
    J Clin Oncol; 2001 Oct; 19(20):4081-7. PubMed ID: 11600611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
    Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
    Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
    Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
    de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
    Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
    Glimelius B; Garmo H; Berglund A; Fredriksson LA; Berglund M; Kohnke H; Byström P; Sørbye H; Wadelius M
    Pharmacogenomics J; 2011 Feb; 11(1):61-71. PubMed ID: 20177420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
    Aparicio J; Vicent JM; Maestu I; Bosch C; Galán A; Busquier I; Llorca C; Garcerá S; Campos JM; López-Tendero P; Balcells M
    Oncology; 2005; 68(1):58-63. PubMed ID: 15809521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
    Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
    Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.